Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2025 on Thursday, March 12, 2026, After Close of U.S.-Based Financial Markets
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 Antibody, in Multiple Sclerosis
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 Antibody, in Multiple Sclerosis
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 Antibody, in Multiple Sclerosis
Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 Antibody, in Multiple Sclerosis
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
New REZOLVE-AD Maintenance Data in Atopic Dermatitis Demonstrate Rezpegaldesleukin Resulted in Durable and New Responses Across Key Disease Measurements with Both Monthly and Quarterly Dosing
Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for its REZOLVE-AD Phase 2b Study of Rezpegaldesleukin in Atopic Dermatitis on February 10, 2026
CORRECTION FROM SOURCE: Video - CEO Clips Bold Ventures Advances Exploration at Burchell and Highlights Ring of Fire
Bold Ventures Provides Update on Burchell Drilling Progress and Announces PDAC Participation at Booth #2610
